What is Multiple Myeloma Phase I MLN9708 Trial?

Category: Others

true

Generic name: Ixazomib (MLN9708)

This trial is an open-label, dose-escalation, Phase 1 study evaluating the safety and tolerability of weekly dosing of the oral form of MLN9708, a second-generation proteasome inhibitor, in adult patients with relapsed and refractory Multiple Myeloma. NCT00963820

No patients have reported taking Multiple Myeloma Phase I MLN9708 Trial.
Last updated:
There are no evaluations for Multiple Myeloma Phase I MLN9708 Trial.